Skip to main content

rituximab

 

Status: One Wales interim decision

Using the agreed starting and stopping criteria, rituximab can be made available within NHS Wales for the fourth-line or later treatment of refractory myasthenia gravis in adults.

The rituximab product with the lowest acquisition cost should be chosen for newly initiated patients. 

The risks and benefits of the off-label use of rituximab for this indication should be clearly stated and discussed with the patient to allow informed consent.

Providers should consult the relevant guidelines on prescribing unlicensed medicines before any off-label medicines are prescribed. 

This advice will be reviewed after 12 months or earlier if new evidence becomes available.

 One Wales Interim Decision with start stop criteria and evidence review: rituximab myasthenia gravis OW12. 2021 (PDF, 168Kb)

Medicine details

Medicine name rituximab
Formulation Concentrate for solution for infusion
Reference number OW12
Indication

For the fourth-line or later treatment of refractory myasthenia gravis in adults.

Company Various
BNF chapter Musculoskeletal & joint diseases
Submission type One Wales
Status One Wales interim decision
Advice number OW12
Date of issue 27/08/2019
Date of last review December 2021
Follow AWTTC: